CEO Shifts, Life Cycle Management On Agenda at Morgan Stanley
The Morgan Stanley Healthcare Conference attracted top management from big pharma, biotech and specialty firms, with Sanofi’s Elias Zerhouni commenting on the company’s strategy in Gaucher’s disease and Mylan expressing confidence in its ability to deliver on a generic Advair that meets FDA’s newly-issued proposed standards for substitutability.
You may also be interested in...
With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.
FDA’s draft guidance requires clinical study but sets a lower bar to generics of GSK’s blockbuster asthma and COPD treatment than company proposed; standards appear poised for warm reception from generic challengers.
Federal Circuit finds claims covering Copaxone’s latest expiring patent are invalid; Mylan says it plans to launch its generic of the MS drug in May 2014.